Janney Montgomery Scott Reaffirms Hold Rating for Supernus Pharmaceuticals, Inc. (SUPN)

Janney Montgomery Scott reaffirmed their hold rating on shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in a research report sent to investors on Wednesday morning. The firm currently has a $47.00 target price on the specialty pharmaceutical company’s stock.

Other equities analysts have also issued reports about the stock. Zacks Investment Research raised shares of Supernus Pharmaceuticals from a hold rating to a buy rating and set a $49.00 target price on the stock in a research report on Thursday, July 13th. Cantor Fitzgerald raised their target price on shares of Supernus Pharmaceuticals from $34.00 to $49.00 and gave the stock a buy rating in a research report on Wednesday, July 5th. Jefferies Group LLC raised their target price on shares of Supernus Pharmaceuticals from $45.00 to $51.00 and gave the stock a buy rating in a research report on Wednesday, June 28th. BidaskClub lowered shares of Supernus Pharmaceuticals from a strong-buy rating to a buy rating in a research report on Tuesday, July 25th. Finally, Stifel Nicolaus reaffirmed a buy rating and set a $47.00 target price (up from $36.00) on shares of Supernus Pharmaceuticals in a research report on Tuesday, July 18th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $48.29.

Supernus Pharmaceuticals (SUPN) opened at 39.00 on Wednesday. The firm’s 50 day moving average price is $44.56 and its 200-day moving average price is $37.95. Supernus Pharmaceuticals has a 12-month low of $17.25 and a 12-month high of $50.05. The stock has a market cap of $1.98 billion, a P/E ratio of 19.68 and a beta of 1.30.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 EPS for the quarter, topping the Zacks’ consensus estimate of $0.24 by $0.08. The business had revenue of $75.83 million for the quarter, compared to analyst estimates of $68.54 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. Equities research analysts anticipate that Supernus Pharmaceuticals will post $1.04 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Janney Montgomery Scott Reaffirms Hold Rating for Supernus Pharmaceuticals, Inc. (SUPN)” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://ledgergazette.com/2017/09/23/janney-montgomery-scott-reaffirms-hold-rating-for-supernus-pharmaceuticals-inc-supn.html.

In related news, CFO Gregory S. Patrick sold 50,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $47.60, for a total transaction of $2,380,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Padmanabh P. Bhatt sold 3,735 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $44.90, for a total transaction of $167,701.50. Following the transaction, the vice president now directly owns 21,209 shares in the company, valued at $952,284.10. The disclosure for this sale can be found here. Over the last three months, insiders have sold 157,444 shares of company stock worth $7,390,810. 6.70% of the stock is currently owned by corporate insiders.

Hedge funds have recently modified their holdings of the stock. Meeder Asset Management Inc. increased its holdings in Supernus Pharmaceuticals by 3,455.2% during the second quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 2,315 shares during the period. Ameritas Investment Partners Inc. purchased a new position in Supernus Pharmaceuticals during the first quarter valued at approximately $127,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Supernus Pharmaceuticals by 278.2% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock valued at $130,000 after buying an additional 2,220 shares during the period. Riverhead Capital Management LLC increased its holdings in Supernus Pharmaceuticals by 91.4% during the second quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 1,462 shares during the period. Finally, Advisor Group Inc. increased its holdings in Supernus Pharmaceuticals by 13.7% during the second quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock valued at $145,000 after buying an additional 410 shares during the period. 95.38% of the stock is currently owned by institutional investors.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply